{"id":70169,"date":"2012-02-22T04:58:23","date_gmt":"2012-02-22T04:58:23","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/a-negative-vote-for-vivus-obesity-drug-says-fda-panel-whisperer.php"},"modified":"2024-08-17T16:23:02","modified_gmt":"2024-08-17T20:23:02","slug":"a-negative-vote-for-vivus-obesity-drug-says-fda-panel-whisperer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pharmacogenomics\/a-negative-vote-for-vivus-obesity-drug-says-fda-panel-whisperer.php","title":{"rendered":"A Negative Vote for Vivus Obesity Drug, Says &#39;FDA Panel Whisperer&#39;"},"content":{"rendered":"<p>MOUNTAIN VIEW, Calif. (TheStreet) -- By day, Joseph Lee  is a graduate student pursuing a PhD in pharmaceutical sciences  and pharmacogenomics. By night, he&#039;s the \"FDA Panel Whisperer\" --  the creator of FDATracker.com, a unique web  site that predicts outcomes of FDA advisory committees based on  the historical voting records and behavioral analysis of  participating panelists. Lee has   crunched the data on the 22 panel members who will sit in  judgment of Vivus(VVUS) and its obesity drug Qnexa  tomorrow and he&#039;s not encouraged. His prediction: 10 experts will  vote to recommend Qnexa approval but the remaining 12 will vote  against. That&#039;s a very close vote, made more so by Lee&#039;s  acknowledgement that one or two votes could swing in either  direction, according to his analysis. Guessing the outcome of any  FDA advisory panel is a big challenge; Vivus&#039; panel is even more  difficult to handicap because FDA invited eight experts who have  not previously participated in any of the obesity panels held  last year. For that reason alone, I wouldn&#039;t necessarily take  Lee&#039;s   Vivus analysis to the bank, but his research is thorough and  a compelling read if you&#039;re at all interested in following  tomorrow&#039;s Qnexa presentations and the volatile deliberations  that will undoubtedly follow. Assessing the risk of birth defects  caused by the topirimate component of Qnexa is likely to be the  focal point of Wednesday&#039;s FDA panel debate. FDA invited Suzanne  Gilboa from the National Center on Birth Defects and Development  Disabilities at the CDC to present at Wednesday&#039;s panel. Her  testimony could prove to be influential on the final vote. Of the  eight \"new\" votes on the Qnexa panel, Lee has three experts  voting yes and five voting no. Twelve experts on Wednesday&#039;s  panel also participated in the last Qnexa panel. They voted 5-7  against the drug previously. This time, Lee has only one of these  experts changing to a positive vote, bringing the tally in this  group to a 6-6 tie. Two additional experts invited to review  Qnexa tomorrow participated in FDA panels for the two other  obesity drugs last year from Arena  Pharmaceuticals(ARNA) and Orexigen  Therapeutics(OREX). Lee predicts these two  experts will split their votes on Qnexa. That&#039;s how Lee comes up  with his prediction for a 10-12 vote against the weight-loss  drug. It&#039;s hard to get a solid read on a consensus Wall Street  expectation for the Qnexa panel, but FDA&#039;s review of the drug  released Friday revealed few surprises. This seems to have left  investors leaning toward predicting a positive vote, although  almost everyone predicts a split\/close vote. Vivus shares rose 7%  Friday after the FDA release of its briefing documents but the  stock was down 3% Tuesday to $11.64 per share. I encourage you to  read Lee&#039;s breakdown on how each of the   panel members may vote on Qnexa based on their voting record  from past obesity drug panels or statements made at other FDA  panels. Tomorrow night, we&#039;ll learn if the \"FDA Panel Whisperer\"  is accurate or not. FDA panel members predicted to vote for  Qnexa&#039;s approval, according to Lee: Melanie Coffin, Eric Felner,  Allison Goldfine, Jessica Henderson, Sanjay Kaul, Michael  Rogawski, Robert Smith, Myrlene Staten, Abraham Thomas, Susan  Yanovski. FDA panel members predicted to vote against Qnexa&#039;s  approval, according to Lee: Erica Brittain, Ken Burman, David  Capuzzi, Robert Clancy, Janet Cragan, Katherine Flegal, Ed Gregg,  Mike Lauer, Elaine Morrato, Sonja Rasmussen, Lamont Weide, Almut  Winterstein. --Written by Adam Feuerstein in Boston. &gt;To  contact the writer of this article, click here:   Adam Feuerstein. &gt;To follow the writer on Twitter, go to  <a href=\"http:\/\/twitter.com\/adamfeuerstein\" rel=\"nofollow\">http:\/\/twitter.com\/adamfeuerstein<\/a>. &gt;To submit a  news tip, send an email to: <a href=\"mailto:tips@thestreet.com\">tips@thestreet.com<\/a>. Follow  TheStreet on Twitter and become a fan on Facebook.&gt;To order reprints of this article,  click here: Reprints<\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.thestreet.com\/story\/11426860\/1\/a-negative-vote-for-vivus-obesity-drug-says-fda-panel-whisperer.html?cm_ven=RSSFeed\" title=\"A Negative Vote for Vivus Obesity Drug, Says &#39;FDA Panel Whisperer&#39;\" rel=\"noopener\">A Negative Vote for Vivus Obesity Drug, Says &#39;FDA Panel Whisperer&#39;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MOUNTAIN VIEW, Calif. (TheStreet) -- By day, Joseph Lee is a graduate student pursuing a PhD in pharmaceutical sciences and pharmacogenomics <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pharmacogenomics\/a-negative-vote-for-vivus-obesity-drug-says-fda-panel-whisperer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246862],"tags":[],"class_list":["post-70169","post","type-post","status-publish","format-standard","hentry","category-pharmacogenomics"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/70169"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=70169"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/70169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=70169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=70169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=70169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}